All PMX-sensitive NSCLC cell lines had at least one mutation in genes controlling cAMP/cGMP metabolism, with 64% of them containing mutations of cAMP catabolic genes (PDE4B-C, PDE8B), cGMP catabolic genes (PDE5A, PDE6A-B, PDE6D), or dual cAMP/cGMP catabolic genes (PDE1A-C, PDE3A-B, PDE10A) (Figure 4E). The gene discussed is PDE6D; the disease is non-small cell lung carcinoma.